Impact of pharmaceutical care on the quality of life of patients with Chagas disease and heart failure: randomized clinical trial

Gilberto M Sperandio da Silva, Mayara C Chambela, Andrea S Sousa, Luiz Henrique C Sangenis, Sergio S Xavier, Andréa R Costa, Pedro Emmanuel A A Brasil, Alejandro M Hasslocher-Moreno, Roberto M Saraiva, Gilberto M Sperandio da Silva, Mayara C Chambela, Andrea S Sousa, Luiz Henrique C Sangenis, Sergio S Xavier, Andréa R Costa, Pedro Emmanuel A A Brasil, Alejandro M Hasslocher-Moreno, Roberto M Saraiva

Abstract

Background: Pharmaceutical care is the direct interaction between pharmacist and patient, in order to improve therapeutic compliance, promote adequate pharmacotherapeutic follow-up, and improve quality of life. Pharmaceutical care may be effective in reducing complications and in improving the quality of life of patients with chronic diseases, like Chagas heart disease, while bringing a positive impact on health system costs. The morbidity and mortality indexes for patients with Chagas heart disease are high, especially if this heart disease is complicated by heart failure. In this setting, we hypothesize that pharmaceutical care might be an important tool for the clinical management of these patients by improving their quality of life, as a better compliance to their treatment and the avoidance and prompt correction of drug-related problems will minimize their symptoms, improve their functional class, and decrease the number of hospital admissions. Therefore, the aim of this trial is to evaluate the contribution of pharmaceutical care to clinical treatment of patients with Chagas heart disease complicated by heart failure.

Methods/design: A prospective, single-center randomized clinical trial will be conducted in patients with Chagas heart disease complicated by heart failure. A total of 88 patients will be randomly assigned into two parallel groups: an intervention group will receive standard care and pharmaceutical care, and a control group will receive only standard care. Both groups will be subjected to a follow-up period of 12 months. The primary outcome of this trial is the evaluation of quality of life, measured by the 36-item short-form and the Minnesota Living with Heart Failure Questionnaire. Secondary outcomes include drug-related problems, exercise tolerance as measured by the standard six-minute-walk test, and compliance.

Discussion: Patients with Chagas heart disease complicated by heart failure under pharmaceutical care are expected to improve their quality of life, present with a lower incidence of drug-related problems, improve their functional capacity, and improve in their compliance to treatment.

Trial registration: ClinicalTrials.gov Identifier: NCT01566617.

Figures

Figure 1
Figure 1
General overview of study protocol. 6MWT, six-minute-walk test; DRPs, drug-related problems; HF, heart failure.

References

    1. World Health Organization. First WHO Report on Neglected Tropical Diseases: Working to Overcome the Global Impact of Neglected Tropical Diseases. Geneva: WHO Press; 2010.
    1. Ministry of Health Brazil. Plano Nacional de Saúde – PNS: 2012–2015. Brasília; 2011.
    1. Ministry of Health Brazil. Brazilian Consensus on Chagas Disease. Rev Soc Bras Med Trop. 2005;38:11–14. doi: 10.1590/S0037-86822005000100003.
    1. Biolo A, Ribeiro AL, Clausell N. Chagas cardiomyopathy – where do we stand after a hundred years? Prog Cardiovasc Dis. 2010;52:300–316. doi: 10.1016/j.pcad.2009.11.008.
    1. Dias JC. The indeterminate form of human chronic Chagas’ disease. A clinical epidemiological review. Rev Soc Bras Med Trop. 1989;22:147–156.
    1. Rassi A Jr, Rassi A, Little WC. Chagas’ heart disease. Clin Cardiol. 2000;23:883–889. doi: 10.1002/clc.4960231205.
    1. Mady C, Nacruth R. Natural history of chronic Chagas’ heart disease: prognosis factors. Sao Paulo Med J. 1995;113:791–796. doi: 10.1590/S1516-31801995000200009.
    1. Marin Neto JA, Simoes MV, Sarabanda AV. Chagas’ heart disease. Arq Bras Cardiol. 1999;72:247–280.
    1. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010;375:1388–1402. doi: 10.1016/S0140-6736(10)60061-X.
    1. Rocha MO, Ribeiro AL, Teixeira MM. Clinical management of chronic Chagas cardiomyopathy. Front Biosci. 2003;8:e44–e54. doi: 10.2741/926.
    1. Coura JR, Borges-Pereira J. Chronic phase of Chagas disease: why should it be treated? A comprehensive review. Mem Inst Oswaldo Cruz. 2011;106:641–645.
    1. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:1977–2016.
    1. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685–691.
    1. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet. 1997;349:1493–1497. doi: 10.1016/S0140-6736(97)04442-5.
    1. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation. 1996;94:2800–2806. doi: 10.1161/01.CIR.94.11.2800.
    1. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet. 1999;353:2001–2007.
    1. Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, Inoue T, Araki R. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis. 2008;52:501–506. doi: 10.1053/j.ajkd.2008.04.031.
    1. Bocchi EA, Braga FG, Ferreira SM, Rohde LE, Oliveira WA, Almeida DR, Moreira MC, Bestetti RB, Bordignon S, Azevedo C, Tinoco EM, Rocha RM, Issa VS, Ferraz A, Cruz F, Guimarães GV, Montera VS, Albuquerque DC, Bacal F, Souza GE, Rossi Neto JM, Clausell NO, Martins SM, Siciliano A, Souza Neto JD, Moreira LF, Teixeira RA, Moura LZ, Beck-da-Silva L, Rassi S. et al.III Brazilian Guidelines on Chronic Heart Failure. Arq Bras Cardiol. 2009;93:3–70.
    1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–717. doi: 10.1056/NEJM199909023411001.
    1. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S. Task Force on Practice Guidelines, American College of Cardiology/American Heart Association; Committee for Practice Guidelines, European Society of Cardiology; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Eur Heart J. 2006;27:1979–2030.
    1. Sadik A, Yousif M, McElnay JC. Pharmaceutical care of patients with heart failure. Br J Clin Pharmacol. 2005;60:183–193. doi: 10.1111/j.1365-2125.2005.02387.x.
    1. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533–543.
    1. Hohmann C, Radziwill R, Klotz JM, Jacobs AH. Health-related quality of life after ischemic stroke: the impact of pharmaceutical interventions on drug therapy (pharmaceutical care concept) Health Qual Life Outcomes. 2010;8:59. doi: 10.1186/1477-7525-8-59.
    1. Neto PR, Marusic S, de Lyra Junior DP, Pilger D, Cruciol-Souza JM, Gaeti WP, Cuman RK. Effect of a 36-month pharmaceutical care program on the coronary heart disease risk in elderly diabetic and hypertensive patients. J Pharm Pharm Sci. 2011;14:249–263.
    1. Correr CJ, Pontarolo R, Souza RAP, Venson R, Melchiors AC, Wiens A. Effect of a pharmaceutical care program on quality of life and satisfaction with pharmacy services in patients with type 2 diabetes mellitus. Braz J Pharm Sci. 2009;45:809–817. doi: 10.1590/S1984-82502009000400027.
    1. Koshman SL, Charrois TL, Simpson SH, McAlister FA, Tsuyuki RT. Pharmacist care of patients with heart failure: a systematic review of randomized trials. Arch Intern Med. 2008;168:687–694. doi: 10.1001/archinte.168.7.687.
    1. Gattis WA, Hasselblad V, Whellan DJ, O’Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med. 1999;159:1939–1945. doi: 10.1001/archinte.159.16.1939.
    1. Niquille A, Bugnon O. Relationship between drug-related problems and health outcomes: a cross-sectional study among cardiovascular patients. Pharm World Sci. 2010;32:512–519. doi: 10.1007/s11096-010-9401-1.
    1. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash) 2001;41:192–199.
    1. Andreazza RS, Silveira De Castro M, Sippel Koche P, Heineck I. Causes of drug-related problems in the emergency room of a hospital in southern Brazil. Gac Sanit. 2011;25:501–506. doi: 10.1016/j.gaceta.2011.05.016.
    1. Zortéa K. Quality of life in chronic diseases. Arq Bras Cardiol. 2010;94:703–703.
    1. Grupo de Investigación en Atención Farmacéutica, Universidad de Granada. Seguimiento farmacoterapéutico: Método Dáder (3ª revisión: 2005) Pharmacy Practice. 2006;4:44–45.
    1. Hobart JC, Williams LS, Moran K, Thompson AJ. Quality of life measurement after stroke: uses and abuses of the SF-36. Stroke. 2002;33:1348–1356. doi: 10.1161/01.STR.0000015030.59594.B3.
    1. Carvalho VO, Guimarães GV, Carrara D, Bacal F, Bocchi EA. Validation of the Portuguese version of the Minnesota Living with Heart Failure Questionnaire. Arq Bras Cardiol. 2009;93:39–44. doi: 10.1590/S0066-782X2009000700008.
    1. Lyra Júnior DP, Marcellini PS, Pelá IR. Effect of pharmaceutical care intervention on blood pressure of elderly outpatients with hypertension. Braz J Pharm Sci. 2008;44:451–457.
    1. Du H, Newton P, Zecchin R, Denniss R, Salamonson Y, Everett B, Currow D, Macdonald P, Davidson P. An intervention to promote physical activity and self-management in people with stable chronic heart failure The Home-Heart-Walk study: study protocol for a randomized controlled trial. Trials. 2011;12:63. doi: 10.1186/1745-6215-12-63.
    1. Kato N, Kinugawa K, Seki S, Shiga T, Hatano M, Yao A, Hirata Y, Kazuma K, Nagai R. Quality of life as an independent predictor for cardiac events and death in patients with heart failure. Circ J. 2011;75:1661–1669. doi: 10.1253/circj.CJ-10-1308.
    1. Ivama AM, Noblat L, de Castro MS, Oliveira NVBV, Jaramillo NM, Rech N. Consenso brasileiro de atenção farmacêutica. Brasília: Organização Panamericana de Saúde; 2002.
    1. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245. doi: 10.1038/clpt.1981.154.
    1. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, Berman LB. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J. 1985;132:919–923.
    1. de Oliveira Junior MT, Guimaraes GV, Barretto AC. The 6 minutes test in heart failure. Arq Bras Cardiol. 1996;67:373–374.
    1. Guimaraes GV, Bellotti G, Bacal F, Mocelin A, Bocchi EA. Can the cardiopulmonary 6-minute walk test reproduce the usual activities of patients with heart failure? Arq Bras Cardiol. 2002;78:553–560.
    1. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74. doi: 10.1097/00005650-198601000-00007.
    1. Impact of the Pharmaceutical Care on the Quality of Life in Patients With Chagas Heart Disease (ChagasCare) .
    1. The National Committee for Ethics in Research-MOH (CONEP/MS) .
    1. Lauritsen JM, Bruus M. EpiData (Version 3.1). A Comprehensive Tool for Validated Entry and Documentation of Data. Odense Denmark: The EpiData Association; 2004.
    1. SPSS Inc. SPSS for Windows, Version 16.0. Chicago: SPSS Inc; 2007.
    1. Lowrie R, Mair FS, Greenlaw N, Forsyth P, Jhund PS, McConnachie A, Rae B, McMurray JJ. Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction. Eur Heart J. 2011;33:314–324.
    1. Oliveira BG, Abreu MN, Abreu CD, Rocha MO, Ribeiro AL. Health-related quality of life in patients with Chagas disease. Rev Soc Bras Med Trop. 2011;44:150–156. doi: 10.1590/S0037-86822011005000002.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅